Sekisui Diagnostics, LLC news

High performance, point-of-care rapid test for the detection of Influenza A&B

Burlington, MA – November 17, 2020 –SEKISUI Diagnostics announces it has received CE Marking (Conformité Européenne) for the OSOM^® Ultra Plus Flu A&B Test and has begun marketing in Europe.

The test utilizes traditional lateral flow technology with performance near or exceeding sensitivity of other reader-based tests without using an

Sekisui announces the decision to invest £14.4 Million in its biopharma CDMO business aimed at cGMP microbial capacity expansion at the existing site in Maidstone, Kent to be completed by the second half of 2022. This investment follows the investment of $1.9 million in its new Bioprocess Innovation Centre, completed in October 2019, and is part of a long-term investment strategy to grow its share of the microbial b